Skip to content

Preparation of herbal powder along with Suspension to evaluate their efficacy in Dyspepsia

Pharmaceutico Analytical Study of Avipattikara Churna and Avipattikara Suspension and their Comparative Clinical Evaluation in Amlapitta with Special Reference to Functional Dyspepsia.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/058115
Enrollment
40
Registered
2023-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K00-K95- Diseases of the digestive system

Interventions

None listed

Sponsors

National Institute of ayurveda jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subject fulfilling the Rome IV criteria (2016) for Functional Dyspepsia. Criteria fulfilled for the last 3 months with symptom onset, at least 6 months prior to diagnosis with one or more of the following symptoms: upper abdominal pain (epigastric pain) or discomfort, postprandial fullness, early satiation, bloating, nausea and belching.

Exclusion criteria

Exclusion criteria: Any kind of organic lesion such as peptic ulcer, tumor of any kind, stricture, or structural deformity. Subject with known history of gastric bleeding, intestinal obstruction or perforation, and previous gastrointestinal surgery. ? Subjects with major systemic illness including cardiac disease, diabetes, hypertension, inflammatory bowel disease etc. ? Patients on prolonged (=6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc., or any other drugs that may have an influence on the outcome of the study like antacids or PPI. ? Subjects currently taking drugs that may affect gastrointestinal motility (e.g., anticholinergic, erythromycin, azithromycin, domperidone, etc.), nonsteroidal anti-inflammatory drugs. ? Patients with a history of hypersensitivity to any of the trial drugs or their ingredients.

Design outcomes

Primary

MeasureTime frame
Changes in FD symptoms in dyspepsia questionnaire.[timeframe: baseline (0-week), 4-week]Timepoint: 4 weeks

Secondary

MeasureTime frame
Changes in QOL in FD patients by , World Health Organization Quality of Life (WHO-QOL) scale [time frame: baseline (0-week), 4-week]Timepoint: 4 weeks

Countries

India

Contacts

Public ContactKrishna Nagar

National Institute of Ayurveda, Jaipur

dras2008@gmail.com9968506854

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026